Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · Scoping review

Clinical evidence for growth-hormone secretagogues supplied for research

What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?

Document identifier
CEI-ES-016
Series
Evidence synthesis
Version
1.0
Published
26 Jan 2025
Last reviewed
26 May 2025
Next review
26 Nov 2026
Identifier
10.71829/cei.syn.16
Certainty
Very low
Cycle
2025 Q1
Review type
Scoping review
Search executed
29 Oct 2024

§1Abstract

§1.1Review question

What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?

§1.2PICO frame

Table 1. The registered PICO frame. Any change made after protocol registration is recorded in the amendment log at §5 and is identified there as post hoc.

ElementAs registered
PopulationAdults without a diagnosed growth-hormone deficiency.
InterventionA growth-hormone-releasing hormone analogue or ghrelin receptor agonist.
ComparatorPlacebo or no treatment.
OutcomesBody composition; functional capacity; any clinical outcome.

§1.3Method in brief

A structured map of the available evidence for a question where the Institute judges that a quantitative synthesis is not yet supportable. A scoping review states what would have to exist before an intervention review could be attempted. The protocol was registered with the Institute's secretariat before the search was executed. The search was run on 29 October 2024 across 8 sources and is reproduced in full at §2. Screening, extraction and certainty assessment were performed independently by two members of the secretariat with disagreement resolved by a third.

§1.4Conclusion

The clinical development of every compound in this group was directed at diagnosis of growth-hormone deficiency, at a specific disease indication, or at nothing beyond phase 1. The Institute identified no randomised trial in adults without growth-hormone deficiency reporting a functional or body-composition outcome for any of these compounds at the doses and schedules under which they are supplied. Claims in this group are graded very low certainty throughout, and the pharmacological observation that a compound raises growth hormone is recorded as a pharmacodynamic fact and not as a clinical outcome.

The conclusion rests on 8 contributing studies, listed with their extracted data at §3 and summarised outcome by outcome at §4.

§1.5Limitations

§1.6Consultation

This review was released for public comment before ratification. Draft synthesis: Clinical evidence for growth-hormone secretagogues supplied for research received 9 submissions. Amendments arising are recorded in the amendment log and are traceable to a numbered submission.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.